Background Thiopurines have been widely accepted as immunosuppressive therapy in inflammatory bowel disease. However, many patients have to discontinue thiopurines due to intolerance or ineffectiveness. A therapeutically beneficial effect of switching from azathioprine (AZA) to mercaptopurine (MP) after developing adverse events (AEs) has been reported. The authors assessed the clinical value of MP therapy after AZA discontinuation due to intolerance and, secondary, due to ineffectiveness.
Introduction
Inflammatory bowel disease (IBD) comprises diseases of the gastrointestinal (GI) tract characterized by chronic inflammation alternating with periods of remission and relapses, including Crohn's disease (CD) and ulcerative colitis (UC). The therapeutic treatment of patients with IBD can be subdivided into an induction and a maintenance phase of therapy. [1, 2] Once remission is achieved by induction therapy, (long-term) maintenance therapy will be initiated.
Step-up therapy typically starts with medications that are usually less potent and allegedly associated with fewer side effects. If those therapies are ineffective, more potent medications will be used. [1] [2] [3] For maintenance therapy of both UC and CD, the first choice immunosuppressant is a thiopurine derivative. [3] The two conventional thiopurines, azathioprine (AZA) and mercaptopurine (MP) are both widely accepted as first-line immunosuppressive therapy. However, in the Netherlands, AZA is the only thiopurine that has been registered as certified treatment for IBD, whereas MP does not have this registration. In 2009, onethird of the whole IBD population was using a thiopurine at the (crosssectional) moment of study, whereas almost half was at that time point not using thiopurines but had used it before. [4] The metabolism of thiopurines is complex involving several enzymatic pathways. It seems that the AZA has a more steady metabolism with less fluctuating metabolite levels based on the fact that AZA bypasses the first-pass effect because it is metabolized into 6-MP after absorption in the liver. [5] Finally, after various enzymatic conversions, the pharmacologically active 6-thioguanine nucleotides (6-TGNs) are generated. [5, 6 ] The 6-TGN metabolites act as purine antagonists and induce cytotoxicity and immunosuppression by inhibition of RNA, DNA and protein synthesis but not when used in proper dosages for anti-inflammatory therapy, usually weight based, being 2.0-2.5 mg/kg for AZA and 1.0-1.5 mg/kg for MP. [7, 8] Especially in lower (IBD-)dosages, 6-TGNs induce apoptosis of T-lymphocytes by inhibition of the small GTPase Rac1. [9] Theoretically, based on its pharmacology and metabolism, the toxicity profile of AZA and MP is essentially similar. [5] Known adverse events (AEs) include GI complaints, flu-like illness, pancreatitis, myelosuppression, hepatotoxicity, arthralgia, and myalgia. [10] Owing to the fact that the chemical structure of AZA consists of an extra imidazole group, it was previously thought that this might contribute to higher number of AEs in AZA users. [11] Although thiopurine treatment is considered effective and relatively safe, it seems that up to 60% of patients with IBD have to discontinue thiopurine therapy within 5 years. The most common reason for discontinuation is the occurrence of intolerable AEs. [12] In the past, several studies have been performed to observe tolerability of MP after prior AZA therapy had to be discontinued due to intolerance. [13] [14] [15] [16] To date, no reports show numbers of efficacy during MP therapy after prior AZA ineffectiveness. In this study, we explored whether patients benefit from MP use after AZA failure. The primary goal of this study was to observe the tolerance of MP after prior AZA intolerance. The secondary outcome was observing if patients clinically benefit from switching to MP, after AZA proved to be ineffective.
Methods
We performed an intercept cohort study regarding all patients treated for IBD at the Department of Gastroenterology and Hepatology at the VU University Medical Centre (Amsterdam, the Netherlands), a third-line referral center for IBD. Patient data regarding demographics and type of therapy of all patients visiting the gastroenterologist due to IBD since 1998 were prospectively gathered and maintained in a database. [12] The database was scrutinized during a 15-year period, from 1998 to 2013. The diagnosis of IBD was ascertained by standard clinical, radiological, histological, and endoscopic assessment. Thiopurines were prescribed according to the step-up approach, in line with national guidelines. [3] All patients were supervised and treated by an experienced IBD gastroenterologist (AvB). Patients with IBD who previously used AZA and subsequently were treated with MP were included in this study. Data were collected from chart reviews.
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Patient Characteristics
The following patient characteristics were collected: age, gender, weight, height, type of IBD (CD, UC, or IBD unclassified), and age of IBD at initiation of MP. All patients with UC and CD were classified according to the Montreal Classification. [17] To determine the duration of IBD, we calculated the number of months between the date of diagnosis until the initiation date of MP. Data on prior intestinal surgical resection were collected as well, because this may interfere with thiopurine absorption and pharmacodynamics, thus affecting the effect of thiopurine therapy.
Characteristics of Thiopurine Use
The following data regarding thiopurine use were collected (if available): date of initiation and (possible) discontinuation of both AZA and MP, dosage of both AZA and MP, reason for discontinuation of AZA or MP, and thiopurine metabolite concentrations [i.e., 6-TGN-therapeutic range 230-400 pmol/8 x 10 8 in red blood cells (RBCs) and 6-methyl-MP (6-MMP)-reference value <5700 pmol/8 x 10 8 RBCs] during AZA and MP therapy, as described in previous studies. [18] The usage of known drugs that can modulate the effect of thiopurine (mesalazine, allopurinol, infliximab, and ribavirin) was documented as well. [19] The activity of the enzyme thiopurine-S-methyltransferase (TPMT) is not determined before the initiation of thiopurine therapy in our center and was therefore not measured in participating patients. To determine the duration of both AZA and MP treatment, the number of months between initiation and discontinuation was calculated. If a patient continued MP, the duration of therapy was calculated from the date of initiation of MP until January 1, 2013. When multiple thiopurine metabolite concentrations were available during treatment, the most recent concentrations were used. Reasons for discontinuation were subdivided into: intolerable adverse reactions, ineffectiveness, ongoing clinical remission, patient's request and "other", such as loss to follow-up. Intolerable adverse reactions were defined as adverse effects of sufficient severity to warrant drug cessation, according to the Common Terminology Criteria for Adverse Events (CTCAE). [20] Adverse reactions were subdivided into myelosuppression, hepatotoxicity, pancreatitis, arthralgia/myalgia, GI complaints, flu-like illness, and other. Myelosuppression was defined as the presence of leukopenia, thrombocytopenia, or hemoglobin concentration below the lower reference limit. Hepatotoxicity was classified according to the World Health Organization toxicity score. [20] Pancreatitis was defined as a combination of (typical) upper abdominal pain with or without radiation to the back, radiological imaging [i.e., ultrasound or computed tomography (CT) of the upper abdomen], increased concentration of C-reactive protein and amylase or lipase level above twice the upper reference limit. Headache, weakness, and fever were considered as flu-like illness. The group "other" AEs consisted of various side effects such as rash, tingling of arms or legs, dizziness, and itching.
Ineffectiveness was defined as the inability to remain in clinical remission as assessed by the IBD specialist. Clinical remission was defined as regression of clinical symptoms, such as no blood or pus in stools and no postprandial abdominal pain or fever, as assessed in a global physician's assessment.
Benefit
Regarding the second goal of this study, benefit of MP was defined as the ongoing use of MP with successfully cessation of corticosteroid therapy without worsening of disease, supported by inflammatory markers and endoscopy findings. Elevated inflammatory markers were considered as Creactive protein above the upper limit of normal, leukocyte count >9.9 x 10 9 /L or fecal calprotectin (FCP) >29 µg/g.
Data Modification
The 6-TGN levels in our center were determined using the slightly modified method developed by Dervieux et al. [18] To compare our data with previously published IBD literature, in which most commonly the method developed by Lennard et al [21] to determine 6-TGN levels has been used, we calculated 6-TGN concentrations by dividing it by 2.6, as described earlier. [22, 23] 8
Statistics
The statistical analysis was performed using IBM SPSS Statistics (version 22.0; IBM Corporation, New York, NY). Continuous variables were expressed as mean with standard deviation, if parametric. Nonparametric variables were expressed as medians with ranges. Categorical variables were expressed as numbers (percentages). Continuous data were compared using an unpaired t test for parametric data or a Mann-Whitney U test for nonparametric data. For categorical data, the χ2 test was used. A P-value of less than 0.05 was considered significant.
Ethics
This study was approved by the Medical Ethics Review Committee (METC) of the VU University Medical Centre with file-number 2015-473. 
Results
The IBD database consisted of 1,425 patients with IBD. In total, 74 (5.2%) patients who were treated with MP after AZA therapy ( Fig. 1) were identified. Thiopurines were administered between March 1989 and January 2013. We analyzed 60 of 74 patients (81%) who experienced ineffectiveness or AEs. The remaining 14 patients discontinued AZA for other reasons (patient's request or ongoing remission) and were excluded from analysis.
Azathioprine Intolerance
Regarding the primary goal of this study, we analyzed 38 patients with IBD, who started MP after discontinuation of AZA due to intolerance. This subgroup consisted of 24 patients with CD, 13 patients with UC and one patient diagnosed with IBD unclassified. Discontinuation of AZA followed after a median duration of 2 months (range 0.2 -239 months). Three patients were rechallenged with AZA, and intolerance reoccurred in all 3 of these patients. After a thiopurine-free interval with a median of 5 months (range 0 -106 months), MP was administered.
Comparing mercaptopurine-tolerant and mercaptopurine-intolerant patients
In 22 (58%) patients, MP was discontinued due to AEs after 0.86 months (range 0.1 -15 months). The remaining 16 (42%) patients did not develop any AEs during the study period and were considered as tolerant for MP. This subgroup consisted of 6 (16%) patients who were still using MP, 6 (16%) patients in whom MP proved to be ineffective, 3 (8%) patients who stopped due to prolonged remission and 1 (3%) patient who stopped at own request ( Table 1) . MP tolerability was neither affected by sex, Montreal classification, abdominal surgery, patient's age, nor type of IBD (P > 0.05). In 21 of 37 (57%) patients, AZA was underdosed (i.e., <2.0 mg/kg), whereas in 16 (42%) patients, MP was underdosed (missing dosages and allopurinol users excluded). Although often underdosed, dosing of both AZA and of MP was similar for all patients, regardless of tolerance to MP (P > 0.05). As expected, the median duration of MP use in patients who tolerated MP was longer than in patients who were intolerant of MP; 15.5 vs. 0.86 months (P < 0.001). The median duration of the preceding AZA therapy was also longer
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(1.2 vs. 5.3 months; P < 0.05) in the group without AE. Concentrations of 6-TGN and 6-MMP between MP-tolerant and MP-intolerant patients were comparable (P > 0.05). Metabolites generated from MP with allopurinol as co-medication were excluded, as allopurinol alters the thiopurine metabolism and thus induces a bias in the results.
Comparing Adverse Events
In Table 2 , the clinical advantage of using MP as opposed to AZA use for each AE has been depicted. As a patient may have more than one AE, the total number of AEs exceeded the number of patients. Interestingly, the articular AE leading to withdrawal of MP was frequently different from the AE that led to discontinuation of AZA. In 18 (38%) of the cases, the same AE occurred.
Mercaptopurine Benefit
Regarding the secondary goal of this study, we analyzed patients who had to stop with AZA due to ineffectiveness and were switched to MP. In total, 22 patients discontinued AZA therapy due to ineffectiveness, after a median of 40.7 months (range 6 -229 months). Four (18%) patients discontinued subsequent MP due to ineffectiveness, whereas 10 (46%) patients appeared to be intolerant of MP. The 8 (36%) remaining patients were still using MP up to January 1, 2013 ( Table 3) . Notable is that a high number of patients having benefit of MP (6 of 8, 75%) used allopurinol as co-medication. In all 6 patients using allopurinol alongside MP, this was started due to ineffectiveness, caused by a preferential thiopurine metabolism leading to ultramethylation, defined as 6-MMP level above 5,700 pmol/8 excluding results of patients using allopurinol alongside MP, only 2 patients remained available for analysis in the benefit group, compared with 11 2 Leukocytes, fecal calprotectin, and C-reactive protein were scored. In case 1 marker was above the upper reference limit, this was scored as moderate. More than 1 elevated marker was scored as elevated. 3 Based on the report of the treating physician.
N/A, not applicable.
Comparing mercaptopurine benefit and non-benefit patients
In the eight patients with ongoing use of MP, this drug was considered to be therapeutically beneficial, in line with a 6-TGN concentration within the therapeutic range (median 269 pmol/8 x 10 8 RBCs). The remaining patients were considered as having no benefit of MP, consistent with low 6-TGN concentrations (median 156 pmol/8 x 10 8 RBC, P = 0.02) ( Table 4) .
Benefit in treatment with MP was neither affected by sex, type of IBD, weight, BMI, abdominal surgery, Montreal classification, nor patient's age.
Comparable to the analysis in the AZA intolerant group, a longer interval between AZA cessation and MP initiation was associated with clinical benefit (4.4 vs. 0.01 months; P < 0.05).
Discussion
Immunosuppression with thiopurines is considered effective and relatively safe and is part of the standard treatment of IBD. [1] [2] [3] However, effectiveness and the ability to tolerate thiopurines is not universal as 60% of the patients discontinue therapy within five years after initiation. [12] In this retrospective study we analyzed 74 patients, who used MP therapy after failing AZA therapy due to various reasons. We report that thiopurines derivative use may be optimized in case of intolerance for or ineffectiveness of AZA by switching to MP in about 37% of patients.
Azathioprine intolerance
We observed that MP was tolerated in 16 of 38 (42%) patients in whom AZA therapy was earlier withdrawn because of AEs. A shorter duration of AZA administration was negatively associated with the tolerance for MP, indicative that immediate clinical appearance of intolerance is thiopurine class specific more than drug derivative specific. Tolerance for a switch to MP was observed in a lower percentage than in earlier reports. [13] [14] [15] [24] [25] [26] Three of these studies were relatively small with less than 20 patients. [24] [25] [26] In another three larger scaled studies (n = 52, 61, and 135, successively), benefit has been reported in 48%, 52% and 60% of patients, respectively. [13] [14] [15] 8 Table 4 Response to MP therapy in patients with AZA ineffectiveness. 0.02* Non-parametric variables are displayed as medians (range). Parametric variables are displayed as means ± SD. *Statistically significant (P < 0.05). MP, mercaptopurine; AZA, azathioprine; CD, Crohn's disease; UC, ulcerative colitis; IBDu, IBD unclassified; BMI, body mass index; RBC, red blood cells 1 Localisation of IBD was scored using the Montreal classification. [17] We suggest several reasons why our results appear to be less advantageous. First, dosing is relevant, as we showed that AZA tended to be underdosed more often than MP for patients intolerant to AZA, suggesting that our findings of reduced tolerability to MP might be influenced by a dosedependent effect.
Second, the duration of AZA therapy; the MP tolerant group had a longer period of time of prior AZA use, therefore it may be questioned whether the documented AEs were genuinely thiopurine induced, instead of symptoms due to disease activity, extra-intestinal manifestations (EIMs) or intercurrent other health issues (e.g. viral infect or other medication).
Third, the VU University Medical Centre is a tertiary referral center, potentially affecting the results in a negative way. Furthermore, our center is a dedicated thiopurine research center. [5, 6, 12, [27] [28] [29] [30] [31] [32] Before cessation of thiopurines, we attempt to optimize therapy first by: split-dose administration, therapeutic drug monitoring (TDM) or specific analyses concerning other potential culprits of witnessed AE, being all factors potentially contributing to a more disadvantageous therapeutic outcome.
Comparing adverse events
When comparing AEs of AZA with the ones observed during MP therapy, we observed less likelihood for hepatotoxicity and arthralgia and a higher likelihood for flulike illness and GI complaints when using AZA. Consistent with earlier reports, the AE leading to AZA withdrawal was frequently different from the AE leading to MP withdrawal, with 38% of the particular AE reoccurring after switching. In previous studies, reoccurrence of the same AE was shown in 26%-56% of patients. [13, 14] We hypothesize that a high number of "aspecific" AEs, such as GI symptoms or flu-like illness, may contribute to this difference, as these symptoms might be caused by numerous causes other than solely thiopurine therapy.
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Mercaptopurine benefit
Twenty-two patients discontinued AZA due to ineffectiveness and switched to MP. Eight (36%) were still using MP as the 14 remaining patients discontinued due to ineffectiveness or development of AE. It has to be mentioned that 6 out of these 8 patients (75%) used allopurinol alongside MP. The co-administration of this drug might account for a better response to therapy for itself, probably making this number an overestimation. Furthermore, dosing of AZA tended to be relatively low, with 15 of 22 (68%) patients underdosed (under 2.0 mg/kg). It might be argued that this in itself explains the ineffectiveness of AZA (although in daily practice, the prescribed dosage may be limited or reduced due to AE as well, which is also consistent with the high number of patients with a skewed metabolism in this group). Underdosing of AZA in itself may account for a higher number of AEs in the adequately dosed MP group. In these series, MP was indeed relatively higher (1.3 mg/kg) dosed than AZA (1.8 mg/kg), leading to 6-TGN concentrations of 156 vs. 102 pmol/8 x 10 8 RBCs.
6-Thioguanine nucleotide concentrations and allopurinol use
6-TGN concentrations appeared to be higher when MP was being used with allopurinol, a statistical trend that became significant when all benefitting MP users, regardless of co-medications, were being compared with all nonbenefitting MP-users, indicative of drug dosage optimization. In general, patients benefitting from a switch to MP after subsequent AZA ineffectiveness had significantly higher 6-TGN levels than non-benefitting patients. Earlier studies showed that improved 6-TGN concentrations are associated with therapeutic success, underlining that TDM is a useful tool to evaluate effectiveness of MP therapy after failing AZA, especially to optimize thiopurine therapy. [12] With this article, we showed the clinical value of MP therapy after subsequent AZA intolerance or ineffectiveness. To our knowledge, effectiveness data after switching thiopurine therapy has not been published before.
Compared with previous studies, we demonstrate that less patients than previously published tolerate MP treatment after AZA intolerance, probably due to stringent optimization of preceding AZA therapy. Finally, we underlined the importance of allopurinol co-administration in patients with insufficient response to conventional thiopurine treatment in patients with a skewed metabolism.
Conclusion
Thiopurine therapy may be therapeutically effectively continued after failing on AZA, particularly when AE on AZA therapy develop after a longer period of administration or when intolerance is observed in patients with IBD of longer duration. Furthermore, a switch to MP therapy after inefficacy on AZA was potentially beneficial when therapy was co-administered with allopurinol, in patients with a skewed metabolism.
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